Accuitive Medical Ventures

The firm is led by Managing Directors Charles Larsen, Thomas O'Donnell and Mark Wan, all former medical-device CEOs who founded and exited their own companies before joining the partnership. Investment decisions are made collectively by this operator group, reflecting the firm's requirement that every GP have CEO-level medtech operating experience.

Accuitive's sourcing relies heavily on the operating networks of its general partners, each of whom spent decades in the medical-device industry before entering venture capital. The firm benefits from referrals through surgeon-specialist relationships, hospital-system administrators and regulatory consultants who worked with the partners during their operating careers.

Accuitive is definitively operator-led. The partnership's governing principle requires that every investment professional previously served as a medical-device CEO. This means portfolio companies receive board-level guidance from investors who have personally managed FDA submissions, manufacturing ramp-ups and hospital-contracting processes.

Accuitive invests across the medical-technology lifecycle, from early-stage venture rounds to pre-IPO financings. The firm typically engages after a company has reached first-in-human data, initial regulatory clearance or early commercial traction, though it will invest earlier when the founding team includes known operators.

Accuitive has historically co-invested alongside other medtech-focused venture firms and strategic corporate investors, particularly in later-stage rounds where syndicate construction involves multiple specialized funds. The firm does not publicly disclose a formal co-investment policy.

Accuitive remains focused on regulated medical devices, diagnostics, digital health and healthcare services requiring FDA or equivalent regulatory pathways. The firm generally avoids pharmaceutical development, biotechnology and non-healthcare technology sectors, where its operator-partner expertise does not apply.